Lever
Lifestyle
- Regular cardiovascular exercise
- Weight management
- Smoking cessation
Blutwerte · Marker
NT-proBNP
N-terminal pro-BNP · NT-pro-B-type Natriuretic Peptide · BNP
Herzmarker
- Einheit:
- pg/mL
NT-proBNP quantifies the level of N-terminal pro-B-type natriuretic peptide, a marker of cardiac ventricular wall stress.
Reference Ranges
Reference
0–125pg/mL
0
125
LowNormalHigh
Reference
Unit · pg/mLReference ranges can vary with age and renal function. Higher values are expected in older adults.
Overview
Übersicht
NT-proBNP, or N-terminal pro-B-type natriuretic peptide, is a biomarker derived from the cleavage of proBNP, a precursor of brain natriuretic peptide (BNP). It is released primarily from the cardiac ventricles in response to increased wall stress and volume overload. NT-proBNP serves as a surrogate marker for cardiac function, particularly in heart failure, where it reflects the severity of ventricular dysfunction. Clinically, NT-proBNP is instrumental in diagnosing and managing heart failure, offering prognostic insights independent of traditional clinical predictors. Elevated levels are associated with adverse outcomes in conditions like acute decompensated heart failure, pulmonary arterial hypertension, and severe aortic stenosis. In the context of athletic performance and biohacking, NT-proBNP can provide information on cardiac stress and recovery, although its primary utility remains in clinical settings. Researchers have noted that NT-proBNP levels can be influenced by factors such as age, renal function, and body mass index, which may confound interpretation. Time of day and fasting status do not significantly affect NT-proBNP levels, making it a stable marker for serial monitoring.
Klinische Bedeutung
Elevated NT-proBNP levels indicate cardiac stress and are associated with heart failure, pulmonary hypertension, and other cardiovascular conditions. Lower levels generally suggest a lower likelihood of heart failure.
Dynamics
Trend Interpretation
Rising Values
Rising NT-proBNP levels suggest worsening cardiac function and may warrant a re-evaluation of heart failure management. Re-test in 4 weeks if levels increase significantly.
Falling Values
Falling levels indicate improved cardiac function or effective treatment response.
Re-test Interval
4 weeks if outside optimal range
Etiology
Causes — High & Low
Cause
Elevated Levels
- Heart failure
- Pulmonary hypertension
- Acute coronary syndrome
- Renal dysfunction
- Severe aortic stenosis
Cause
Low Levels
- Effective heart failure treatment
- Low cardiac stress
- Young age
- Good renal function
- Low body mass index
Protocol
How to Optimize
Lever
Nutrition
- Low-sodium diet
- High-fiber foods
- Omega-3 fatty acids
Note:
Consult a healthcare provider for personalized advice, especially if managing heart failure.
Testing Guidelines
✓Fasting Not Required
✓Not Time-Sensitive
Testing Frequency
Every 6 months for heart failure patients, annually for others with risk factors.
Interfering Factors
- Renal impairment
- Obesity
- Age
Related Peptides & Hormones
Bnp
hormone or peptideDirectly measures
Open Research Questions
Current research suggests that the optimal reference ranges and targets for NT-proBNP in various conditions, such as Takayasu arteritis and neuroendocrine tumors, remain debated. Researchers have not yet established the extent to which confounding factors, like age and sex, influence NT-proBNP levels across different diseases. Additionally, clinical questions regarding the biomarker's predictive value for disease progression in asymptomatic patients and its role in guiding treatment decisions remain unanswered.
29 Research Publications
247
Total Citations
13
Human/RCT
2.0
Avg. Influence
2024
Latest
Sort
Filter
01Top
#01
N-Terminal B-type Natriuretic Peptide in Heart Failure.
ReviewInfluence1.0
59
Researchers found that NT-proBNP is a crucial biomarker in heart failure, particularly in acute decompensated heart failure. It offers prognostic information and is essential for monitoring patients receiving specific heart failure treatments.
02Top
#02
Evidence based application of BNP/NT-proBNP testing in heart failure.
ReviewInfluence2.0
50
This review summarized evidence on the application of BNP and NT-proBNP testing in heart failure. Researchers highlighted the importance of these biomarkers in diagnosing heart failure and discussed their potential roles in prognosis and therapy guidance.
03Top
#03
NT-proBNP in Different Patient Groups of COPD: A Systematic Review and Meta-Analysis.
Meta-AnalysisInfluence6.0
34
Researchers conducted a systematic review to evaluate NT-proBNP levels in COPD patients. They found that NT-proBNP levels were significantly higher in patients with acute exacerbations and those with severe COPD, indicating its potential role in assessing cardiovascular stress.
04
#04
Detection of cardioembolic stroke with B-type natriuretic peptide or N-terminal pro-BNP: a comparative diagnostic meta-analysis.
Meta-AnalysisInfluence2.0
32
Researchers conducted a meta-analysis comparing the diagnostic efficacy of BNP and NT-proBNP in detecting cardioembolic stroke. They found that while both biomarkers have similar overall diagnostic accuracies, BNP demonstrated superior sensitivity.
05
#05
Angiotensin Receptor-Neprilysin Inhibitors and the Natriuretic Peptide Axis.
ReviewInfluence1.0
20
This review discussed the effects of angiotensin receptor-neprilysin inhibitor therapy on the natriuretic peptide axis, including NT-proBNP. Researchers noted that NT-proBNP levels correlate with improvements in cardiac function during treatment.
06
#06
Biomarkers in Takayasu arteritis.
Wen Dan, et al. · International journal of cardiology · 2023
Review
15
This study examined various biomarkers, including NT-proBNP, in patients with Takayasu arteritis (TA). Researchers found that these biomarkers are valuable for early diagnosis, evaluating disease activity, and guiding clinical treatment options in TA.
Key findings
- 01Researchers observed that Takayasu arteritis involves complex interactions between immune system components and inflammation.
- 02They identified several biomarkers, including cytokines and autoantibodies, that may help in understanding the disease.
- 03The study highlights the need for further research to clarify the role of these biomarkers in Takayasu arteritis.
07
#07
Cardiac Biomarkers in Patients With Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY TAVR Trial.
Human
11
Researchers found that higher levels of NT-proBNP in patients with asymptomatic severe aortic stenosis were associated with higher event rates for adverse outcomes. However, the study suggested limited value for single measurements of NT-proBNP to guide the timing of transcatheter aortic valve replacement.
08
#08
The Indian Consensus Document on cardiac biomarker.
Review
5
This study examined the role of cardiac biomarkers in diagnosing and managing heart failure in India. Researchers found that biomarkers can indicate the presence and severity of congestive heart failure (CHF) and may provide clinical benefits compared to conventional assessments.
09
#09
High-Sensitivity Troponin T, NT-proBNP, and Cognitive Outcomes in SPRINT.
HumanInfluence1.0
5
In the SPRINT study, researchers found that lower levels of NT-proBNP were associated with greater cognitive benefits from intensive blood pressure treatment. Higher NT-proBNP levels indicated a higher risk of mild cognitive impairment or probable dementia.
10
#10
NT-proBNP as a neuroendocrine tumor biomarker: beyond heart failure.
Human
4
This study explored NT-proBNP concentrations in patients with metastatic neuroendocrine tumors. Researchers observed that NT-proBNP levels correlated with higher tumor burden and disease progression, suggesting its role in monitoring tumor status.
Publication Trend
Research publications about NT-proBNP over time
9totalTrack your bloodwork in PepStack
Log lab results, track trends and optimize your biomarkers over time.
Legal Disclaimer
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer